Home World News Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate... World News Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 387 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Study Shows Thymic Health is Linked to Cancer Patients’ Response to... October 16, 2025 Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6... February 17, 2021 Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously... June 19, 2024 Helping Kids Cope With Cancer: “Your Stories” Podcast January 11, 2021 Load more HOT NEWS Nursing Professor Who Used Her Breast Cancer Diagnosis as a Teaching... Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates... Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced... 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail...
